GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entheon Biomedical Corp (XCNQ:ENBI) » Definitions » Liabilities-to-Assets
中文

Entheon Biomedical (XCNQ:ENBI) Liabilities-to-Assets : 0.21 (As of Nov. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Entheon Biomedical Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Entheon Biomedical's Total Liabilities for the quarter that ended in Nov. 2023 was C$0.09 Mil. Entheon Biomedical's Total Assets for the quarter that ended in Nov. 2023 was C$0.40 Mil. Therefore, Entheon Biomedical's Liabilities-to-Assets Ratio for the quarter that ended in Nov. 2023 was 0.21.


Entheon Biomedical Liabilities-to-Assets Historical Data

The historical data trend for Entheon Biomedical's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Entheon Biomedical Liabilities-to-Assets Chart

Entheon Biomedical Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Nov21 Nov22 Nov23
Liabilities-to-Assets
Get a 7-Day Free Trial 0.02 0.02 0.09 0.20 0.21

Entheon Biomedical Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23
Liabilities-to-Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.20 0.23 0.16 0.10 0.21

Competitive Comparison of Entheon Biomedical's Liabilities-to-Assets

For the Biotechnology subindustry, Entheon Biomedical's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Entheon Biomedical's Liabilities-to-Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entheon Biomedical's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Entheon Biomedical's Liabilities-to-Assets falls into.



Entheon Biomedical Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Entheon Biomedical's Liabilities-to-Assets Ratio for the fiscal year that ended in Nov. 2023 is calculated as:

Liabilities-to-Assets (A: Nov. 2023 )=Total Liabilities/Total Assets
=0.085/0.401
=0.21

Entheon Biomedical's Liabilities-to-Assets Ratio for the quarter that ended in Nov. 2023 is calculated as

Liabilities-to-Assets (Q: Nov. 2023 )=Total Liabilities/Total Assets
=0.085/0.401
=0.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Entheon Biomedical  (XCNQ:ENBI) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


Entheon Biomedical Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of Entheon Biomedical's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Entheon Biomedical (XCNQ:ENBI) Business Description

Traded in Other Exchanges
Address
999 West Broadway Street, Suite 720, Vancouver, BC, CAN, V5Z 1K5
Entheon Biomedical Corp is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective Dimethyltryptamine based psychedelic therapeutic products (DMT Products) for the purposes of treating addiction and substance use disorders. Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics, and licensed psychiatrists in the United States, certain countries in the European Union, and throughout Canada.

Entheon Biomedical (XCNQ:ENBI) Headlines

No Headlines